A study by Ebenbuild confirms strong predictive performance of patient-specific lung digital twins, validated against clinical imaging data. The model's accuracy was demonstrated through a correlation coefficient of 0.95 with experimental data, enabling locally resolved predictions of aerosol deposition at the individual patient level.
The Phase 1 trial demonstrated that repeated immunisation with PD01A is safe and well-tolerated, with a substantial reduction in alpha-synuclein oligomers and stable motor scores. The results suggest that PD01A may offer a promising strategy for long-term management of Parkinson's disease.
A monoclonal antibody targeting mutant huntingtin protein effectively binds and depletes the protein from cell culture supernatants, blocking its secretion and uptake. This suggests that mAB C6-17 could interfere with pathological processes of mutant huntingtin spreading in vivo.
Eternygen presents preclinical study data demonstrating INDY inhibition reverses nonalcoholic steatohepatitis (NASH) in a diet-induced mouse model. The treatment also reduces liver injury and inflammation.
A team of international scientists decoded the molecular characteristics of a fatal subtype of leukemia in children, paving the way for new therapeutic approaches. The study identified genetic aberrations and altered gene expression programs that lead to tumorigenesis, providing potential druggable targets.